Jason Wright
Corporate Officer/Principal at Proclara Biosciences, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John F. Dee | M | 66 |
Proclara Biosciences, Inc.
 Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | 2 years |
| Roxanne Bales | F | - |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | 16 years |
| Hampus Jacob Hillerstrom | M | - |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | 18 years |
| April Sheedy | F | - |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | - |
| Peter T. Smedvig | M | 78 |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | - |
| Paul David Goldenheim | M | - |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | - |
| Peter Ryser | M | 72 |
Swiss Federal Institute of Technology
| 26 years |
| Friedrich Fahrni | M | 82 |
Swiss Federal Institute of Technology
| 24 years |
| Hans Schoepflin | M | - |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | - |
| Richard Fisher | M | - |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | 16 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jonathan Solomon | M | 47 |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | 9 years |
| Franz Hefti | M | 76 |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | 3 years |
| Suzanne Bruhn | M | 60 |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | 1 years |
| Meret Gaugler | M | - |
Swiss Federal Institute of Technology
| 5 years |
| Pascal Jean-Noël Noth | M | - |
Swiss Federal Institute of Technology
| 4 years |
| Roland Reber | M | 55 |
Swiss Federal Institute of Technology
| 4 years |
| Maurus Maissen | M | 50 |
Swiss Federal Institute of Technology
| 6 years |
| Alfred Scheidegger | M | 67 |
Swiss Federal Institute of Technology
| 3 years |
| Cyril Vancura | M | - |
Swiss Federal Institute of Technology
| 7 years |
| Patrick Aebischer | M | 70 |
Swiss Federal Institute of Technology
| 16 years |
| Oliver Wyrsch | M | 47 |
Swiss Federal Institute of Technology
| 5 years |
| Anne Marie de Jonge Schuermans | M | 52 |
Swiss Federal Institute of Technology
| 4 years |
| Lukas Bucher | M | - |
Swiss Federal Institute of Technology
| 6 years |
| Lino Guzzella | M | 66 |
Swiss Federal Institute of Technology
| - |
| Nico Dosenbach | M | - |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | - |
| Christian Bruch | M | 54 |
Swiss Federal Institute of Technology
| 4 years |
| Andrea Orzati | M | 51 |
Swiss Federal Institute of Technology
| 4 years |
| Marc von Waldkirch | M | 50 |
Swiss Federal Institute of Technology
| 5 years |
| Marc A. Pointet | M | 50 |
Swiss Federal Institute of Technology
| 4 years |
| Sibyl Anwander Phan-huy | M | 61 |
Swiss Federal Institute of Technology
| 13 years |
| Dong Liang Chang | M | 48 |
Swiss Federal Institute of Technology
| 3 years |
| Raymond Schnidrig | M | 55 |
Swiss Federal Institute of Technology
| 5 years |
| Elena Cortona | M | 54 |
Swiss Federal Institute of Technology
| 4 years |
| Sabrina Contratto | F | 51 |
Swiss Federal Institute of Technology
| 4 years |
| Robin Maly | M | - |
Swiss Federal Institute of Technology
| 4 years |
| Wendy Alexandra Franks | M | - |
Swiss Federal Institute of Technology
| 5 years |
| Kim Nguyen | M | - |
Swiss Federal Institute of Technology
| 4 years |
| Olivier Verscheure | M | 52 |
Swiss Federal Institute of Technology
| 3 years |
| Dominik A. Lysek | M | - |
Swiss Federal Institute of Technology
| 4 years |
| Niklaus Mannhart | M | 57 |
Swiss Federal Institute of Technology
| 6 years |
| Verena Vescoli | M | 53 |
Swiss Federal Institute of Technology
| 4 years |
| Kimberley S. Gannon | M | - |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | - |
| Wolfgang Fichtner | M | 72 |
Swiss Federal Institute of Technology
| 5 years |
| Stefano Lecchini | M | - |
Swiss Federal Institute of Technology
| 6 years |
| Bernhard Vögeli | M | - |
Swiss Federal Institute of Technology
| 9 years |
| Daniel Lynch | M | 65 |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | - |
| Serguei Okhonin | M | - |
Swiss Federal Institute of Technology
| 3 years |
| Urs Wälchli | M | 63 |
Swiss Federal Institute of Technology
| 1 years |
| Alexander Ernst | M | 57 |
Swiss Federal Institute of Technology
| 3 years |
| Francesco Piazza | M | - |
Swiss Federal Institute of Technology
| 7 years |
| Kenneth A. Buckfire | M | - |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | - |
| Dario Neri | M | 61 |
Swiss Federal Institute of Technology
| 21 years |
| Christoph Niederberger | M | 47 |
Swiss Federal Institute of Technology
| 4 years |
| Thomas Müller | M | - |
Swiss Federal Institute of Technology
| 4 years |
| Ulrich W. Suter | M | 80 |
Swiss Federal Institute of Technology
| 4 years |
| Pascal Mathis | M | - |
Swiss Federal Institute of Technology
| 6 years |
| Barbara Frei-Spreiter | M | 54 |
Swiss Federal Institute of Technology
| 3 years |
| Michael Simon Geissmann | M | 46 |
Swiss Federal Institute of Technology
| 4 years |
| Herbert Bay | M | - |
Swiss Federal Institute of Technology
| 1 years |
| Peter Cech | M | - |
Swiss Federal Institute of Technology
| 3 years |
| Espen Edwin Wiik | M | 52 |
Swiss Federal Institute of Technology
| 1 years |
| Felix Graf | M | 57 |
Swiss Federal Institute of Technology
| 3 years |
| André Frei | M | 48 |
Swiss Federal Institute of Technology
| 5 years |
| Damir Filipovic | M | 54 |
Swiss Federal Institute of Technology
| 3 years |
| Gabriel Brenna | M | 51 |
Swiss Federal Institute of Technology
| 3 years |
| Joachim Oechslin | M | 54 |
Swiss Federal Institute of Technology
| 1 years |
| Frank Lehmann | M | - |
Swiss Federal Institute of Technology
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 52 | 77.61% |
| United States | 15 | 22.39% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jason Wright
- Personal Network
